Revvity (RVTY) said Wednesday the US Food and Drug Administration has approved the company's Auto-Pure 2400 liquid handling platform with the T-SPOT.TB diagnostic test for latent tuberculosis.
The Auto-Pure 2400 platform was launched outside the US in 2024, Revvity said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.